Clinical Trials Directory

Trials / Completed

CompletedNCT03395574

Effect of Terlipressin on Cerebral Oxygen Saturation During Liver Transplantation

Effect of Terlipressin on Cerebral Oxygen Saturation and Cerebral Blood Flow During Living Donor Liver Transplantation

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Kasr El Aini Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

in our study the investigators aim to assess the effect of terlipressin on cerebral oxygenation monitored by cerebral oxymetry and cerebral blood flow measured by transcranial doppler.

Detailed description

All patients will receive 6ml /kg/h Ringer acetate solution as a maintenance intraoperative fluid. If pulse pressure variations (PPV) is more than 15%, the patient will be considered as fluid responder and will receive a 250-ml bolus of albumin 5% to maintain PPV ≤15%. Blood transfusion will be given based on a hemoglobin level (\< 7 g/dl) in both (control group) and (terlipressin group). Other blood products will be transfused guided by lab result; Fresh frozen plasma will be given when INR \> 2 and platelets will be given when platelets \<30.000/mm3. The patients will be randomly allocated into 2 groups; Group T (Terlipressin group) and group S (Normal saline 0.9%). For (terlipressin group) all patients will receive loading dose of terlipressin (1mg diluted with 50 ml of normal saline 0.9% solution over 30 min) and it will be maintained by continuous infusion at rate of 160 μg per hour (8 ml/h). For (control group) all patient will receive 50 ml of normal saline 0.9% solution over 30 min and will be maintained continuous infusion at rate of 8 ml/h. Drugs will be prepared by the nurse and the investigator will be blinded to the drug given.

Conditions

Interventions

TypeNameDescription
DRUGTerlipressindrug will be given after 30 minutes of induction of anesthesia
DRUGNormal salinedrug will be given after 30 minutes as placebo in control group

Timeline

Start date
2018-01-25
Primary completion
2018-11-25
Completion
2018-11-25
First posted
2018-01-10
Last updated
2018-12-24

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT03395574. Inclusion in this directory is not an endorsement.